Retraction Note to: Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells

Autor: Andrew K Geissler, James W. Mier, Qingjun Liu, David J. Panka

Publikováno v: Molecular Cancer, Vol 20, Iss 1, Pp 1-1 (2021)
Molecular Cancer

The studies reported herein were undertaken to determine if the angiostatic function of p53 could be exploited as an adjunct to VEGF-targeted therapy in the treatment of renal cell carcinoma (RCC). Nude/beige mice bearing human RCC xenografts were tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9df2439969c69c00b0b5ae1cab7cb912
https://doaj.org/article/d1148a1c84c347f38f7fd62368cbf081

Novel drugs that target the metabolic reprogramming in renal cell cancer

Autor: Andrew K Geissler, James W. Mier, Johannes C. van der Mijn, David J. Panka, Henk M.W. Verheul

Publikováno v: van der Mijn, J C, Panka, D J, Geissler, A K, Verheul, H M & Mier, J W 2016, ' Novel drugs that target the metabolic reprogramming in renal cell cancer ', CANCER & METABOLISM, vol. 4 . https://doi.org/10.1186/s40170-016-0154-8
CANCER & METABOLISM, 4. BioMed Central Ltd.
Cancer & Metabolism

Molecular profiling studies of tumor tissue from patients with clear cell renal cell cancer (ccRCC) have revealed extensive metabolic reprogramming in this disease. Associations were found between metabolic reprogramming, histopathologic Fuhrman grad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::040d47ad78e8a310f9600274b073b384